Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011033391 - METHODS OF TREATING A PATIENT RECEIVING A CARDIAC STENT IMPLANT

Publication Number WO/2011/033391
Publication Date 24.03.2011
International Application No. PCT/IB2010/002701
International Filing Date 21.10.2010
IPC
A61K 38/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61K 38/37 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
36Blood coagulation or fibrinolysis factors
37Factors VIII
CPC
A61K 38/1709
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
1703from vertebrates
1709from mammals
A61P 41/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
41Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
A61P 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A61P 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
A61P 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
G01N 2800/32
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
32Cardiovascular disorders
Applicants
  • VIRON THERAPEUTICS INC. [CA]/[CA] (AllExceptUS)
  • LUCAS, Alexandra, R. [US]/[US] (UsOnly)
Inventors
  • LUCAS, Alexandra, R.
Agents
  • BIEKER-BRADY, Kristina
Priority Data
61/242,79916.09.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF TREATING A PATIENT RECEIVING A CARDIAC STENT IMPLANT
(FR) PROCÉDÉS DE TRAITEMENT D'UN PATIENT AYANT SUBI UNE IMPLANTATION D'ENDOPROTHÈSE CORONAIRE
Abstract
(EN)
Methods of treating a patient receiving a cardiac stent implant including the steps of: (i) monitoring the circulating level of Tn I or CK-MB in the patient; and (ii) administering SERP-I to the patient in an amount sufficient to prevent the circulating level of Tn I or CK-MB from exceeding a specified threshold for the first 24 hours following implantation are disclosed. A specified value of SERP-I is sufficient for preventing circulating level of Tn I or CK-MB from exceeding a specified threshold during the first 24 hours following implantation. The dosing regime of SERP-I to the patient starting within 24 hours of post-implantation is also disclosed.
(FR)
La présente invention concerne des procédés de traitement d'un patient ayant subi une implantation d'endoprothèse coronaire, qui consistent: i) à contrôler le niveau de circulation de TnI ou de CK-MB chez le patient; et ii) à lui administrer une quantité suffisante de SERP-1 pour empêcher que le niveau de circulation de TnI ou de CK-MB ne dépasse un seuil prescrit pendant les 24 premières heures suivant l'implantation de l'endoprothèse. L'invention concerne également des procédés de traitement d'un patient ayant subi une implantation d'endoprothèse coronaire, qui consistent: i) à contrôler le niveau de circulation de TnI ou de CK-MB chez le patient; et ii) à lui administrer une quantité suffisante de SERP-1 pour obtenir une exposition de SERP-1 représentant au moins une valeur prescrite au cours des 24 premières heures suivant l'implantation de l'endoprothèse. L'invention concerne en outre des procédés de traitement d'un patient ayant subi une implantation d'endoprothèse coronaire, qui consistent: i) à contrôler le niveau de circulation de TnI ou de CK-MB chez le patient; et ii) à lui administrer SERP-1 dans les 24 heures suivant l'implantation de l'endoprothèse.
Latest bibliographic data on file with the International Bureau